cladribine has been researched along with Duncan Disease in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (65.00) | 18.2507 |
| 2000's | 6 (30.00) | 29.6817 |
| 2010's | 1 (5.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoffman, PC | 1 |
| Aguilar, J; Al-Katib, A; del Busto, R; Johnson, LB; Obeid, KM; Sharma, M; Szpunar, S | 1 |
| Baudo, F; deCataldo, F | 1 |
| André, M; Costantini, S; Ferrant, A; Francart, J; Lambert, C; Layios, N; Michaux, L; Robert, A; Sonet, A; Van Den Neste, E | 1 |
| Blonski, JZ; Gora-Tybor, J; Kasznicki, M; Robak, T; Smolewski, P; Urbanska-Rys, H | 1 |
| Blonski, JZ; Cebula, B; Chojnowski, K; Robak, T; Smolewski, P; Szmigielska-Kaplon, A | 1 |
| Hanada, S; Otsuka, M; Owatari, S; Takeshita, T | 1 |
| Delannoy, A; Michaux, JL | 1 |
| Juliusson, G; Liliemark, J | 2 |
| Hakimian, D; Tallman, MS | 1 |
| Cheson, BD | 1 |
| Duvic, M; Estey, E; Kantarjian, H; Keating, MJ; Kurzrock, R; O'Brien, S; Pierce, S; Robertson, LE; Stass, S | 1 |
| Larson, RA; Mick, R; O'Brien, SM; Ratain, MJ; Spielberger, RT | 1 |
| Johnson, SA | 1 |
| Góra-Tybor, J; Robak, T | 1 |
| Algeri, R; Birtolo, S; Forconi, F; Galieni, P; Lauria, F; Raspadori, D; Rondelli, D; Tura, S; Ventura, MA; Zinzani, PL | 1 |
| Piro, LD; Saven, A | 1 |
| Kong, LR; Kuzel, TM; Rademaker, AW; Roenigk, HH; Rosen, ST; Samuelson, E; Tallman, MS | 1 |
| Bromidge, TJ; Howe, DJ; Johnson, SA; Rule, SA | 1 |
8 review(s) available for cladribine and Duncan Disease
| Article | Year |
|---|---|
Immune hemolytic anemia--selected topics.
Topics: Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Blood Group Incompatibility; Cladribine; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulins, Intravenous; Immunosuppressive Agents; Lymphocyte Subsets; Lymphoproliferative Disorders; Postoperative Complications; Rituximab; Splenectomy; Transfusion Reaction; Transplantation; Transplantation, Homologous; Venous Thromboembolism; Vidarabine | 2009 |
2-Chloro-2'-deoxyadenosine.
Topics: Adult; Antineoplastic Agents; Child; Cladribine; Humans; Lymphoproliferative Disorders; Phosphorylation | 1995 |
2-Chloro-2'-deoxyadenosine--clinical, biochemical and pharmacokinetic considerations.
Topics: Antimetabolites, Antineoplastic; Cladribine; Humans; Lymphoproliferative Disorders | 1994 |
Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders.
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Drug Resistance; Humans; Lymphoproliferative Disorders; Pentostatin; Purine Nucleosides; Vidarabine | 1995 |
Purine analogs in lymphoproliferative disorders.
Topics: Antineoplastic Agents; Cladribine; Humans; Leukemia; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Multiple Myeloma; Pentostatin; Vidarabine | 1993 |
Purine analogues in the management of lymphoproliferative diseases.
Topics: Antineoplastic Agents; Cladribine; Humans; Lymphoproliferative Disorders; Pentostatin; Vidarabine | 1996 |
[Clinical pharmacology of 2-chlorodeoxyadenosine (Cladribine)].
Topics: Animals; Antineoplastic Agents; Cladribine; Humans; Leukemia L1210; Leukemia, Hairy Cell; Lymphoproliferative Disorders | 1996 |
2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders.
Topics: Antineoplastic Agents; Cladribine; Clinical Trials as Topic; Humans; Lymphoproliferative Disorders | 1996 |
6 trial(s) available for cladribine and Duncan Disease
| Article | Year |
|---|---|
High incidence of complications after 2-chloro-2'-deoxyadenosine combined with cyclophosphamide in patients with advanced lymphoproliferative malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Female; Humans; Leukopenia; Lymphoproliferative Disorders; Male; Middle Aged; Neoplasms, Second Primary; Opportunistic Infections; Survival Analysis | 2004 |
Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Hematologic Diseases; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Opportunistic Infections; Remission Induction; Rituximab; Salvage Therapy; Survival Analysis | 2004 |
Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Male; Middle Aged; Rituximab; Treatment Outcome | 2006 |
2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders.
Topics: Adult; Aged; Antigens, CD; Cladribine; Female; Hematopoiesis; Humans; Immunophenotyping; Leukemia, Prolymphocytic, T-Cell; Leukocyte Count; Lymphoproliferative Disorders; Male; Middle Aged; Mycosis Fungoides | 1994 |
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Chi-Square Distribution; Cladribine; Diarrhea; Digestive System Diseases; Drug Administration Schedule; Fatigue; Female; Fever; Hematologic Diseases; Humans; Immunocompromised Host; Infections; Infusions, Intravenous; Logistic Models; Lymphoproliferative Disorders; Male; Middle Aged; Treatment Outcome | 1996 |
2-Chlorodeoxyadenosine in cutaneous T-cell lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Lymphoproliferative Disorders; Male; Middle Aged; Prognosis; Skin Neoplasms; Survival Rate | 1997 |
6 other study(ies) available for cladribine and Duncan Disease
| Article | Year |
|---|---|
Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Pneumocystis carinii; Pneumonia, Pneumocystis; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Vidarabine | 2012 |
Successful treatment with 2-chlorodeoxyadenosine of secondary lesions of the central nervous system in low-grade lymphoid malignancies.
Topics: Central Nervous System Neoplasms; Cladribine; Disease-Free Survival; Female; Humans; Leukemia, Hairy Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Middle Aged; Neoplasms, Second Primary; Treatment Outcome; Waldenstrom Macroglobulinemia | 2002 |
[Remarkable response to cladribine in the treatment for hairy B cell lymphoproliferative disorder].
Topics: Antineoplastic Agents; B-Lymphocytes; Cladribine; Female; Humans; Lymphoproliferative Disorders; Middle Aged; Treatment Outcome | 2007 |
2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Agents; Chronic Disease; Cladribine; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Recurrence; Treatment Outcome | 1997 |
Heterogeneity of clonal lymphocytes with regard to bcl-2 protein concentration and cell size.
Topics: Antigens, CD19; Antineoplastic Agents; B-Lymphocyte Subsets; Cell Separation; Cell Size; Cladribine; Clone Cells; Flow Cytometry; Humans; Lymphoproliferative Disorders; Proto-Oncogene Proteins c-bcl-2 | 1997 |
[A new effective therapy of hairy cell leukemia and other lymphoproliferative diseases].
Topics: 2-Chloroadenosine; Cladribine; Deoxyadenosines; Humans; Leukemia, Hairy Cell; Lymphoproliferative Disorders | 1991 |